BioSyent Announces Third Quarter Results

MISSISSAUGA, ONTARIO (TSX VENTURE: RX) today released its third quarter 2007 financial results for the period ending September 30, 2007. Sales increased from $1,040,608 in the first nine months of 2006 to $1,050,013 in the first nine months of 2007, an increase of 1%. Gross margin of the company for the first nine months of 2007 was 68.8% compared to 68.1% in the corresponding prior year period. The company earned a profit of $31,410 in the first nine months of 2007 compared to a profit of $296,491 in the corresponding period in the previous year. This translates to basic earnings per share of $0.003 for Year-To-Date (YTD) September, 2007 (0.024 cents per share YTD September, 2006). This lower profit is predominantly due to selling and marketing expenses to promote FeraMAX(TM) which was first shipped in April 2007. FeraMAX is now nationally distributed and is being detailed and promoted across Canada.

As at September 30, 2007 the Company had working capital of $1,236,080 (including cash and cash equivalents of $1,229,647).

BioSyent continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905) 206-0013 (905) 206-1413 (FAX) Email: rgoehrum@biosyent.com Website: www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024